News

Latest Press Releases

BioPorto to provide additional patient information in support of its US application for regulatory clearance of The NGAL Test™ for pediatric risk assessment of AKI

The Company expects to submit a revised and supplemented application in Q2 2020.

November 18, 2019

BioPorto submits answers to the FDA regarding The NGAL Test™ for risk assessment for AKI in pediatric patients

Response supplements the BioPorto application for pediatric use of The NGAL Test™ for risk assessment of acute kidney injury (AKI).

October 17, 2019

BioPorto Submits Pediatric Application to FDA for The NGAL Test™ Under Breakthrough Designation

First test focused on risk assessment of Acute Kidney Injury in pediatric patients.

May 15, 2019

BioPorto Appoints New President of BioPorto Diagnostics, Inc.

Company Plans to Bring Novel Kidney Diagnostic to US Market

April 15, 2019

BioPorto A/S - Annual General Meeting

BioPorto A/S held its Annual General Meeting where the shareholders took note of the report on the Company’s activities and adopted the 2018 Annual Report.

March 18, 2019

Video Playlist

View recent videos from proactiveinvestors.com
You can navigate current and past videos using the playlist control in the top right of the video player.